INVITAE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0005 USD | -94.44% |
|
-66.67% | -99.92% |
| 04-25 | Labcorp beats quarterly estimates on strong testing demand | RE |
| 04-25 | Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln | RE |
| Sales 2021 | 460M 36.86B | Sales 2022 | 516M 41.33B | Capitalization | 452M 36.17B |
|---|---|---|---|---|---|
| Net income 2021 | -379M -30.34B | Net income 2022 | -3.11B -249B | EV / Sales 2021 | 8.98 x |
| Net Debt 2021 | 679M 54.33B | Net Debt 2022 | 1.2B 96.38B | EV / Sales 2022 | 3.21 x |
| P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-0.14
x | Employees | 1,700 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98.19% |
More Fundamentals
* Assessed data
More news
Latest transcript on Invitae Corporation
More recommendations
More press releases
More news
| 1 day | -94.44% | ||
| 1 week | -66.67% | ||
| Current month | -95.45% | ||
| 1 month | -96.15% | ||
| 3 months | -99.88% | ||
| 6 months | -99.91% | ||
| Current year | -99.92% |
1 week
0.00
0.01
1 month
0.000.01
Current year
0.000.65
1 year
0.001.67
3 years
0.0037.50
5 years
0.0061.59
10 years
0.0061.59
| Managers | Title | Age | Since |
|---|---|---|---|
Randal Scott
FOU | Founder | 66 | 12/01/10 |
Kenneth Knight
CEO | Chief Executive Officer | 63 | 28/06/20 |
Ana Schrank
DFI | Director of Finance/CFO | - | 01/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 03/11/15 | |
Randal Scott
FOU | Founder | 66 | 12/01/10 |
Eric Aguiar
BRD | Director/Board Member | 62 | 31/08/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.69% | 16 M€ | -8.49% | ||
| 0.63% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.0005 | -94.44% | 271,771 |
| 25/04/24 | 0.009 | +800.00% | 1,428,884 |
| 24/04/24 | 0.001 | -72.22% | 178,541 |
| 23/04/24 | 0.0036 | +16.13% | 279,073 |
| 22/04/24 | 0.0031 | +106.67% | 444,994 |
End-of-day quote OTC Markets, April 25, 2024
More quotes
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -99.92% | 143K | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M |
- Stock Market
- Equities
- NVTA.Q Stock
